Correction to: Two years later: Is the SARS-CoV-2 pandemic still having an impact on emergency surgery? An international cross-sectional survey among WSES members

Background: The SARS-CoV-2 pandemic is still ongoing and a major challenge for health care services worldwide. In the first WSES COVID-19 emergency surgery survey, a strong negative impact on emergency surgery (ES) had been described already early in the pandemic situation. However, the knowledge is limited about current effects of the pandemic on patient flow through emergency rooms, daily routine and decision making in ES as well as their changes over time during the last two pandemic years. This second WSES COVID-19 emergency surgery survey investigates the impact of the SARS-CoV-2 pandemic on ES during the course of the pandemic. Methods: A web survey had been distributed to medical specialists in ES during a four-week period from January 2022, investigating the impact of the pandemic on patients and septic diseases both requiring ES, structural problems due to the pandemic and time-to-intervention in ES routine. Results: 367 collaborators from 59 countries responded to the survey. The majority indicated that the pandemic still significantly impacts on treatment and outcome of surgical emergency patients (83.1% and 78.5%, respectively). As reasons, the collaborators reported decreased case load in ES (44.7%), but patients presenting with more prolonged and severe diseases, especially concerning perforated appendicitis (62.1%) and diverticulitis (57.5%). Otherwise, approximately 50% of the participants still observe a delay in time-to-intervention in ES compared with the situation before the pandemic. Relevant causes leading to enlarged time-to-intervention in ES during the pandemic are persistent problems with in-hospital logistics, lacks in medical staff as well as operating room and intensive care capacities during the pandemic. This leads not only to the need for triage or transferring of ES patients to other hospitals, reported by 64.0% and 48.8% of the collaborators, respectively, but also to paradigm shifts in treatment modalities to non-operative approaches reported by 67.3% of the participants, especially in uncomplicated appendicitis, cholecystitis and multiple-recurrent diverticulitis. Conclusions: The SARS-CoV-2 pandemic still significantly impacts on care and outcome of patients in ES. Well-known problems with in-hospital logistics are not sufficiently resolved by now; however, medical staff shortages and reduced capacities have been dramatically aggravated over last two pandemic years

Synthesis, characterization and biological activities of Ni(II), Cu(II) and UO2(VI) complexes of N '-((2Z,3E)-3-(hydroxyimino)butan-2-ylidene)-2-phenylacetohydrazide

WOS: 000449141100005In this study, the mononuclear Ni(II), Cu(II) and UO2(VI) complexes of N'-((2Z,3E)-3-(hydroxyimino) butan-2-ylidene)-2-phenylacetohydrazide ligand (LH2) have been synthesized. All compounds have been characterized by using elemental, spectral, X-ray analyses and magnetic moment measurements. The IR spectra of Ni(II) and UO2(VI) complexes show that LH2 has coordinated to the metal ions in tridentate manner with ON2 donor sites of deprotonated phenolic -OH, the imine N atoms of hydrazone (CO=N) and oxime (C=N-OH) groups. In the Cu(II) complex, the ligand is ketoamine form and bond to metal ion via carbonyl oxygen, imine nitrogen atoms of oxime and hydrazone groups. The spectral and magnetic studies show that the Ni(II), and Cu(II) complexes exhibit octahedral geometry. UO2(VI) complex has a monomeric structure constructed of a hexagonal bipyramidal uranyl centre with two monodentate ligand in trans-position. Newly complexes have been tested for antimicrobial and antioxidant activity. All of the complexes have active against L mono cytogenes, M. luteus, S. epidermis, B. cereus, S. typhi H, E. coli, Klebsiella pneumonia, Br. abortus and C albicans. Results of antioxidant activities indicate that the ligand and complexes have multiple antioxidant activities, such as total antioxidant (phosphomolybdenum) assay, reducing power, free radical (DPPH center dot), superoxide anion and ABTS' scavenging activity tests. The Ni(II) complex exhibited more effective total antioxidant activity and reducing power than BHA and trolox but weak the ABTS(center dot+), free radical (DPPH center dot), and superoxide anion (O-2(center dot-)) scavenging activity. The ABTS(center dot+), and DPPH* scavenging activities of Cu(II) were found excellent in comparison with standards. Ni(II), and UO2(VI) acted a powerful inhibitor of superoxide anion. The Cu(II) complex crystallized in the monoclinic space group C2/c, while UO2(VI) complex crystallized in the monoclinic space group P2(1)/c. (C) 2018 Elsevier B.V. All rights reserved